ALL patients with low levels of CD8+ PD1+ in the peripheral blood have a significant survival advantage over patients with high levels of CD8+ PD1+ in the peripheral circulation (median 720 vs 1620 days, p = 0.0284) (Fig. 7D). The gene discussed is PDCD1; the disease is acute lymphoblastic leukemia.